Objective: To study the epidemiology of candidemia and to identify risk factors for mortality among adult patients
Material And Method: Retrospective analysis of patients with candidemia in a 2400-bed tertiary-care university hospital in Bangkok, Thailand from June 2006 to May 2009.
Results: During the study period, 147 patients (50% male) with clinically significant candidemia were identified, with a mean age of 61 years. The underlying conditions included renal failure (47%), abdominal surgery within 30 days (31%), diabetes (27%), hematologic malignancies (25%), solid malignancies (25%), neutropenia (23%), and liver disease (11%). Nearly all patients (98%) received antibacterial therapy within 30 days. The four most common Candida species were C. albicans (39%), C. tropicalis (28%), C. glabrata (22%) and C. parapsilosis (6%). Only sixty-nine patients (47%) received appropriate antifungal therapy within 72 hours. The 28-day all-cause mortality was 59%. By multivariate analysis, the independent risk factors associated with mortality were neutropenia from chemotherapy OR = 9.12 (2.94-28.31), septic shock OR = 3.66 (1.54-8.66), ICU admission OR = 3.18 (1.27-7.92), inappropriate antifungal therapy within 72 hours OR = 2.38 (1.07-5.28) and renal failure OR = 2.34 (1.07-5.13).
Conclusion: Adult patients with candidemia had a high mortality rate particularly those receiving an inappropriate antifungal therapy. Empirical antifungal therapy should be considered in selected patients on the basis of underlying conditions, severity of illness and risk factors for mortality.
Download full-text PDF |
Source |
---|
J Oncol Pharm Pract
January 2025
Department of Pharmacy, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
Study Objective: Complex pharmacotherapy in cancer patients increases the likelihood of drug-drug interactions (DDIs). Pharmacists play a critical role in the identification and management of DDIs. The aim of present study was to evaluate the role of pharmacist in identifying antifungal drug interactions in cancer patients and providing relevant recommendations.
View Article and Find Full Text PDFAMB Express
January 2025
Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
Candida albicans is a commensal fungus that naturally inhabits the vagina. However, overgrowth of C. albicans can result in vulvovaginal candidiasis (VVC), one of the most prevalent fungal infections affecting women.
View Article and Find Full Text PDFPituitary
January 2025
Division of Endocrinology, Santiago de Compostela University and Ciber OBN, Santiago, Spain.
Purpose: A recent update of consensus guidelines for the management of Cushing's disease (CD) included indications for medical therapy. However, there is limited evidence regarding their implementation in clinical practice. This study aimed to evaluate current medical therapy approaches by expert pituitary centers through an audit conducted to validate the criteria of Pituitary Tumors Centers of Excellence (PTCOEs) and provide an initial standard of medical care for CD.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Department of Respiratory Diseases, KU Leuven University Hospitals Leuven Gasthuisberg Campus, Leuven, Belgium
We report on a fatal case of invasive fungal rhinosinusitis with after lung transplantation. After endoscopic treatment and adjuvant medical therapy with isavuconazole, caspofungin and an investigational antifungal drug, there was a good clinical response with absence of endoscopic and radiographic disease. However, the patient developed disease recurrence, with signs of intracranial involvement on MRI, for which urgent endoscopic sinus surgery was performed and isavuconazole was restarted.
View Article and Find Full Text PDFBMJ Open
January 2025
Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Introduction: Graft-versus-host disease (GvHD) remains a major complication of allogeneic stem cell transplantation (allo-SCT), affecting 30-70% of patients (representing 800 new patients per year in the UK). The risk is higher in patients undergoing unrelated allo-SCT. About 1 in 10 patients die as a result of GvHD or through complications of its treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!